KEMENTERIAN KESIHATAN MALAYSIA
(*Ministry of Health Malaysia*)
Bahagian Regulatori Farmasi Negara (NPRA)
Lot 36, Jalan Prof. Diraja Ungku Aziz,
46200 Petaling Jaya
Selangor
MALAYSIA

No. Telefon : 03 - 7883 5400
Portal Rasmi : www.npra.gov.my

Ruj. Kami : (19) dlm. NPRA/PPPK/01/04

Tarikh : 15 Januari 2026

SEMUA PEMEGANG PENDAFTARAN PRODUK

SEMUA PERSATUAN BERKENAAN

(SEPERTI DI SENARAI EDARAN)

Tuan/Puan,

PENGEMASKINIAN *DRUG REGISTRATION GUIDANCE DOCUMENT* (DRGD) BERKAITAN PERMOHONAN VARIASI PRODUK BERDAFTAR: TEMPOH MASA PEMPROSESAN BAGI SEMUA KATEGORI PRODUK DAN PENGENALAN MEKANISME *RELIANCE* BAGI PRODUK FARMASEUTIKAL

Saya merujuk kepada perkara di atas.

2. Dimaklumkan bahawa Jawatankuasa Penilaian Produk (JKPP) dalam mesyuaratnya Bil. 18/2025 pada 18 Disember 2025 telah bersetuju dengan cadangan pengemaskinian *Drug Registration Guidance Document* (DRGD) berkaitan permohonan variasi produk berdaftar, khususnya melibatkan:

a) Pengemaskinian **tempoh masa pemprosesan** bagi semua kategori produk; dan

b) Pengenalan dan pelaksanaan **mekanisme *reliance*** bagi permohonan variasi produk farmaseutikal termasuk produk biologik yang telah diluluskan oleh agensi regulatori rujukan Bahagian Regulatori Farmasi Negara (NPRA)

3. Pengemaskinian ini merupakan susulan kepada penemuan aktiviti WHO *Benchmarking*, pelaksanaan kajian rintis (*pilot study*) oleh NPRA serta keperluan untuk meningkatkan kecekapan regulatori, pengurangan duplikasi penilaian dan meningkatkan ketelusan proses penilaian variasi.

4. Sehubungan dengan itu, **Perkara 20.1 (Variation)** dalam DRGD akan dikemas kini bagi merangkumi perkara-perkara berikut:

a) Penetapan **tempoh masa pemprosesan yang baharu** bagi kategori MiV, MiV-PA, MaV dan permohonan *grouping/bundling;*

b) Pelaksanaan **mekanisme *reliance*** bagi produk farmaseutikal termasuk produk biologik yang telah mendapat kelulusan sekurang-kurangnya daripada satu agensi regulatori rujukan NPRA; dan

c) Keperluan dokumen sokongan serta tatacara permohonan melalui sistem QUEST.

5. Pemegang Pendaftaran Produk (PRH) hendaklah memastikan semua permohonan variasi dikemukakan **selaras dengan pengemaskinian DRGD ini**, termasuk pematuhan kepada tempoh masa yang ditetapkan dan syarat-syarat yang digariskan bagi permohonan di bawah mekanisme *reliance* seperti yang dinyatakan pada **LAMPIRAN I**. Tempoh masa yang ditetapkan melalui pengemaskinian ini akan menggantikan peruntukan tempoh masa sedia ada yang dinyatakan dalam *Malaysian Variation Guideline for Pharmaceutical Products* (MVG), *Malaysian Variation Guideline for Biologics* (MVGB) dan *Malaysian Variation Guideline for Natural (Traditional Medicine & Homeopathy) and Health Supplement Products.*

6. Pengemaskinian ini bertujuan untuk memastikan proses pengawalseliaan variasi produk berdaftar dilaksanakan dengan lebih cekap, telus dan selaras dengan amalan terbaik antarabangsa, tanpa menjejaskan aspek kualiti, keselamatan dan keberkesanan produk.

7. Dimaklumkan bahawa tarikh kuat kuasa pengemaskinian ini adalah **SERTA-MERTA** mulai tarikh pekeliling ini dikeluarkan.

Sekian, terima kasih.

"MALAYSIA MADANI"

"BERKHIDMAT UNTUK NEGARA"

Saya yang menjalankan amanah,

(ROSLIZA LAJIS) RPh. 3376

Timbalan Pengarah
b.p. Pengarah
Bahagian Regulatori Farmasi Negara
Kementerian Kesihatan Malaysia

yky/nms/RL/pppk
✉ noralsyah@npra.gov.my/ kianyee@npra.gov.my
☎ +603 – 7883 5569/ 5586

s.k. 1. Pengarah Bahagian Regulatori Farmasi Negara, KKM
2. Semua Timbalan Pengarah, NPRA, KKM

SENARAI EDARAN

1. Presiden
   Pharmaceutical Association of Malaysia (PhAMA)
   C-18-2, 3 Two Square (Dataran 3 2)
   No. 2, Jalan 19/1, Section 19,
   46300 Petaling Jaya, Selangor.

2. Presiden
   Persatuan Industri Farmaseutikal Malaysia (MOPI)
   Global Business & Convention Centre
   Mezzanine Floor, Block A,
   No. 8, Jalan 19/1, Section 19,
   46300 Petaling Jaya, Selangor.

3. Presiden
   Malaysian Association of Pharmaceutical Suppliers (MAPS)
   c/o Medispec (M) Sdn Bhd
   B-1-07, Block B, Jalan SS25/22,
   Mayang Avenue, Taman Mayang
   47301 Petaling Jaya, Selangor

4. Presiden
   Direct Selling Association of Malaysia (DSAM)
   SO-21-08, Menara 1, Strata Office,
   No. 3 Jalan Bangsar, KL Eco City
   59200 Kuala Lumpur.

5. Presiden
   Malaysian Direct Selling Industry Development Association (MDSIDA)
   Unit 709, Block A, Level 7,
   Kelana Business Centre,
   97, Jalan SS 7/2,
   Kelana Jaya,
   47301 Petaling Jaya, Selangor.

6. Malaysian Dietary Supplement Association (MADSA)
   Tower Level 3, Axis, 2, Jalan 51a/223,
   Seksyen 51a, 46100 Petaling Jaya,
   Selangor.

7. Presiden
   Persatuan Pengeluar Ubat Cina Malaysia (PPUCM)
   Lot 41, Jalan BRP 9/2B,
   Kawasan Perindustrian, Taman Bukit Rahman Putra,
   47000 Sungai Buloh, Selangor.

8. Presiden
   Federation of Chinese Physicians & Medicine Dealers Associations of Malaysia (FCPMDAM)
   10-11, 13th Floor, Menara Hai-O (Sun Complex),
   Jalan Bukit Bintang,
   55100 Kuala Lumpur.

9. Presiden
   Malaysian Chinese Medical Association (MCMA)
   No.2, Jalan Hang Jebat,
   50150 Kuala Lumpur.

10. Presiden
    Persatuan Pengeluar-Pengeluar Ubat Traditional Melayu Malaysia (PURBATAMA)
    Lot 292, Jalan Shahab 1, Shahab Perdana
    Jalan Sultanah Sambungan
    05150 Alor Setar, Kedah.

11. Presiden
    Pertubuhan Perubatan Tradisional India Malaysia (PEPTIM)
    No 8A, Lorong Sg Rasau 27,
    Off Jalan Batu 3 Lama,
    41300, Klang, Selangor.

12. Presiden
    Majlis Perubatan Homeopathy Malaysia (MPHM)
    No 36-1, Jalan 4/146, Metro Center,
    Bandar Tasik Selatan,
    57000 Kuala Lumpur.

13. Presiden
    Federation of Complementary & Natural Medical Associations Malaysia (FCNMAM)
    B-06-02, 2nd Floor Block B,
    Garden City Business Centre,
    Jalan Dagang Besar, Taman Dagang,
    68000 Ampang, Selangor.

14. Presiden
    Gabungan Pertubuhan Pengamal Perubatan Melayu Malaysia (GAPERA)
    Pejabat Sekretariat Gapera,
    C-0-2, Setiawangsa Business Suites, Jalan Setiawangsa 11,
    54200 Setiawangsa, Kuala Lumpur.

LAMPIRAN I

DRGD Julai 2025	DRGD Januari 2026
20. AMENDMENTS TO PARTICULARS OF A REGISTERED PRODUCT Throughout the life cycle of a registered product, changes to improve product efficacy, quality and safety are likely to occur. Therefore, the applicant shall inform the Authority of any changes or amendments made to particulars of a registered product. **20.1 Variation** a) Variation refers to the change of particulars of a registered product. No change of any particulars of a registered product [except for Minor Variation Notification (MiV-N)] shall be made without prior approval from NPRA. b) All supporting documents shall be submitted in accordance with the specified conditions for each type of variation. c) Variation applications and processing fees shall be made according to specific product categories in the Malaysian Variation Guideline (MVG). d) If deemed necessary, NPRA reserves the right to request for additional supporting documents and variation approval letters from other regulatory bodies for all product categories. e) The registration of a product shall be reviewed for suspension or cancellation if changes that fall under Major Variation (MaV) and Minor Variation Prior Approval (MiV-PA) are implemented without prior approval of the Authority. f) Variation application shall be submitted through the online QUEST system.	**20. AMENDMENTS TO PARTICULARS OF A REGISTERED PRODUCT** Throughout the life cycle of a registered product, changes to improve product efficacy, quality and safety are likely to occur. Therefore, the applicant shall inform the Authority of any changes or amendments made to particulars of a registered product. **20.1 Variation** a) Variation refers to the change of particulars of a registered product. No change of any particulars of a registered product [except for Minor Variation Notification (MiV-N)] shall be made without prior approval from NPRA. b) All supporting documents shall be submitted in accordance with the specified conditions for each type of variation. c) Variation applications and processing fees shall be made according to specific product categories in the Malaysian Variation Guideline (MVG). d) If deemed necessary, NPRA reserves the right to request for additional supporting documents and variation approval letters from other regulatory bodies for all product categories. e) The registration of a product shall be reviewed for suspension or cancellation if changes that fall under Major Variation (MaV) and Minor Variation Prior Approval (MiV-PA) are implemented without prior approval of the Authority. f) Variation application shall be submitted through the online QUEST system. **g) Variation applications that have been approved by at least one of DCA's reference countries are eligible for submission via the**

DRGD Julai 2025	DRGD Januari 2026
	Reliance pathway. Please refer to Section 20.1.3 for further details.
20.1.1 Variation Application for Pharmaceutical Products Variation application for pharmaceutical products shall be done according to the Malaysian Variation Guideline (MVG). **References:** i. *Bil. (2) dlm. BPFK/PPP/07/25, Arahan Pengarah Kanan Perkhidmatan Farmasi Bil. 3 Tahun 2013: Direktif Untuk Melaksanakan* Malaysian Variation Guideline (MVG) (29 April 2013) ii. *Bil (7) dlm. NPRA/PPPK/01/04, Pekeliling Berkenaan Pengemaskinian Garis Panduan Malaysian Variation Guideline for Pharmaceutical Products* (14 July 2022) For unregulated drug substances, kindly note that only the following sections are required and will depend on the type of variation being applied. This is applicable until further notice: i. General Information (Nomenclature, Structure, General Properties) ii. Manufacturer Details iii. Specification of API iv. Batch Analysis v. Certificate of Analysis (COA) from API manufacturer vi. Certificate of Analysis (COA) from finished product manufacturer vii. Justification of Specification viii. Certificates of Suitability (CEP) and its related sections ix. Drug Master File (DMF) and its related sections x. Certificate of GMP for API Manufacturer xi. Other Supporting Documents	**20.1.1 Variation Application for Pharmaceutical Products** Variation application for pharmaceutical products shall be done according to the Malaysian Variation Guideline (MVG). **References:** iii. *Bil. (2) dlm. BPFK/PPP/07/25, Arahan Pengarah Kanan Perkhidmatan Farmasi Bil. 3 Tahun 2013: Direktif Untuk Melaksanakan* Malaysian Variation Guideline (MVG) (29 April 2013) iv. *Bil (7) dlm. NPRA/PPPK/01/04, Pekeliling Berkenaan Pengemaskinian Garis Panduan Malaysian Variation Guideline for Pharmaceutical Products* (14 July 2022) For unregulated drug substances, kindly note that only the following sections are required and will depend on the type of variation being applied. This is applicable until further notice: i. General Information (Nomenclature, Structure, General Properties) ii. Manufacturer Details iii. Specification of API iv. Batch Analysis v. Certificate of Analysis (COA) from API manufacturer vi. Certificate of Analysis (COA) from finished product manufacturer vii. Justification of Specification viii. Certificates of Suitability (CEP) and its related sections ix. Drug Master File (DMF) and its related sections x. Certificate of GMP for API Manufacturer xi. Other Supporting Documents

DRGD Julai 2025	DRGD Januari 2026
20.1.2 Variation Application for Health Supplement and Natural Products Variation application for Health Supplement Products and Natural Products shall be done according to the Malaysian Variation Guideline (MVG) for Natural (Traditional Medicine & Homeopathy) and Health Supplement Products (Abridged Evaluation). **Reference:** Directive No. 14, 2016. *BPFK/PPP/07/25(45)*: *Direktif Untuk Melaksanakan* Malaysian Variation Guideline (MVG) for Natural (Traditional Medicine & Homeopathy) and Health Supplement Products (Abridged Evaluation) (26 July 2016)	**20.1.2 Variation Application for Biological Products** Variation application for biologics shall be done according to the Malaysian Variation Guidelines for Biologics (MVGB). **Reference:** Directive No. 2, 2017. *BPFK/PPP/07/25(7)Jld.1*: *Direktif Untuk Melaksanakan* Malaysian Variation Guideline for Biologics (MVGB) (15 February 2017)
20.1.3 Variation Application for Biological Products Variation application for biologics shall be done according to the Malaysian Variation Guidelines for Biologics (MVGB). **Reference:** Directive No. 2, 2017. *BPFK/PPP/07/25(7)Jld.1*: *Direktif Untuk Melaksanakan* Malaysian Variation Guideline for Biologics (MVGB) (15 February 2017)	**20.1.3 Variation reliance (for pharmaceutical & biological products only)** **1. A Letter of Intent (LOI) or cover letter needs to be submitted to request the use of reliance for the application and should clearly list all relevant variation categories.** **2. Official approval letter or notification of the post-approval changes from the chosen reference agency/ WHO.** **3. An assessment report from the chosen reference agency/WHO may be required as the approval letter may not include details of the approved changes. For variations accompanied by an assessment report, it is strongly recommended to provide the report at the time of submission to facilitate early verification of sameness.** **4. Q&A documentation will be requested during evaluation (if required).** **5. An overall summary of changes, presented in a comparative tabulated format showing both the approved and proposed changes (where applicable), should be provided. Please specify**

DRGD Julai 2025	DRGD Januari 2026
	the file name of each submitted document and indicate its location in the QUEST3+ system.
	NOTES: • **Please ensure that the variations submitted are in accordance with those submitted in the reference agency.** • **It is not advisable to bundle them with other variations that are not part of the reliance submission. The timeline will not be applicable if the submission includes other variations that are not part of the reliance submission.** • **Variation applications submitted under the reliance pathway may be switched to the standard variation evaluation timeline if deemed ineligible for reliance. This may occur in situations such as:** i. **When the approval letter contains limited information, for example when the details of the approved changes are not clearly described.** ii. **When additional evaluation is warranted, such as when the proposed changes cannot be verified against the approval letter or the assessment report.**
	20.1.4 Variation Application for Health Supplement and Natural Products **Variation application for Health Supplement Products and Natural Products shall be done according to the Malaysian Variation Guideline (MVG) for Natural (Traditional Medicine & Homeopathy) and Health Supplement Products (Abridged Evaluation).**

DRGD Julai 2025	DRGD Januari 2026
	Reference: Directive No. 14, 2016. *BPFK/PPP/07/25(45)*: *Direktif Untuk Melaksanakan* Malaysian Variation Guideline (MVG) for Natural (Traditional Medicine & Homeopathy) and Health Supplement Products (Abridged Evaluation) (26 July 2016)

20.1.5 Variation Timeline

Variation (Pharmaceutical & biological products)		Timeline : (working days)
MiV-N or MiVB-N	Maximum of 5* *PRH may submit up to a maximum of 5 concurrent MiV-N/MiVN-B categories per registered product. The review timeline may be extended if more than 5 concurrent MiV-N/MiVN-B categories are submitted.	30
MiV-PA or MiVB-PA	Maximum of 3* *PRH may submit up to a maximum of 3 concurrent MiV- PA/MiVB-PA categories per registered product. The review timeline may be extended if more than 3 concurrent MiV- PA/MiVB-PA categories are submitted *Inclusion of a MiV-PA2* under MiV-PA/MiVB-PA for safety-related changes – Tell & do "Tell & Do" If the application fulfills the requirements as per MVG/MVGB Guideline, NPRA shall approve the proposed change. Changes can be implemented immediately after submission	90
MaV or MaVB	Maximum of 3*	120

DRGD Julai 2025	DRGD Januari 2026		
		*PRH may submit up to a maximum of 3 concurrent MaV/MaVB categories per registered product. The review timeline may be extended if more than 3 concurrent MaV/MaVB categories are submitted.	
	Grouping (bundle applications)	Maximum of 5 variation categories including a maximum of 3 MaV/MaVB categories * *PRH may submit up to a maximum of 5 variation categories concurrently including a maximum of 3 MaV/MaVB categories per registered product. The review timeline may be extended if more than 3 concurrent MaV/MaVB categories are submitted.	150
		Other than the grouping/bundle above	180

Variation timelines for reliance (pharmaceutical & biological products only)

Type of variation groupings	Timeline (wd)
Including MaV/MaVB (maximum of 10 categories*)	Not more than 100
Including MaV/MaVB (more than 10 categories*)	Not more than 150
Excluding MaV/MaVB	Not more than 80

*Inclusive of MiV-N Post-approval Changes Reliance

DRGD Julai 2025	DRGD Januari 2026		
	Variations (TMHS)		Timeline (working days)
	MiV-N	Maximum of 5* *PRH may submit up to a maximum of 5 concurrent MiV-N categories per registered product. The review timeline may be extended if more than 5 concurrent MiV-N categories are submitted.	10
	MiV-PA	Maximum of 3* *PRH may submit up to a maximum of 3 concurrent MiV- PA categories per registered product. The review timeline may be extended if more than 3 concurrent MiV- PA categories are submitted	70
	MaV	Maximum of 3* *PRH may submit up to a maximum of 3 concurrent MaV categories per registered product. The review timeline may be extended if more than 3 concurrent MaV applications are submitted.	100
	Grouping (bundle applications)	Maximum of 5 variation applications including a maximum of 3 MaV applications* *PRH may submit up to a maximum of 5 variation categories concurrently including a maximum of 3 MaV categories per registered product. The review timeline may be extended if more than 3 concurrent MaV categories are submitted	120

DRGD Julai 2025	DRGD Januari 2026

	Other than the grouping/bundle above	150

Notes to PRHs:

1. Timelines for PRH to reply to each correspondence according to the category of products and variation types are as follows: failure to meet these timelines may result in application rejection.
   a) For pharmaceutical products: 45 wd (for MiV-PA and MiVB-PA) and 60 wd (for MaV, MaVB, Grouping/Bundle applications)
   b) For TMHS products: 20 wd (for MiV-PA) and 30 wd (for MaV, Grouping/Bundle applications)

2. For pharmaceutical and biological products only: To ensure a smooth process, all PRHs must attach a cover letter/summary of changes for the intended variation application via Quest3+. The cover letter/summary of changes should include the following:
   a) Proposed variation category
   b) A brief description of the proposed variation with justification
   c) A declaration confirming the fulfilment of all requirements within the suggested category
   d) Approvals from the country of origin's National Regulatory Agency or reference agencies (if any)
   e) Current and proposed changes to the dossier's tabulated format information. Please specify the file name of each document submitted and indicate its location in QUEST3+ system.
   f) A declaration that there is no change except for the proposed change

3. Natural products with therapeutic claims and health supplements with disease risk reduction claims shall follow the revised variation timelines for pharmaceutical products, excluding the variation timelines for reliance.